Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Income from Continuing Operations (2016 - 2025)

Guided Therapeutics' Income from Continuing Operations history spans 15 years, with the latest figure at 742000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 13.46% year-over-year to 742000.0; the TTM value through Sep 2025 reached 2630000.0, down 22.27%, while the annual FY2024 figure was 2417000.0, 30.73% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 742000.0 at Guided Therapeutics, up from 809000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 75000.0 in Q3 2021 and bottomed at 1807000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 677000.0 (2023), against an average of 752368.42.
  • The largest annual shift saw Income from Continuing Operations soared 84.68% in 2021 before it crashed 1369.33% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 444000.0 in 2021, then crashed by 306.98% to 1807000.0 in 2022, then soared by 78.64% to 386000.0 in 2023, then plummeted by 68.91% to 652000.0 in 2024, then decreased by 13.8% to 742000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Income from Continuing Operations are 742000.0 (Q3 2025), 809000.0 (Q2 2025), and 427000.0 (Q1 2025).